Histidine-Tryptophan-Ketoglutarate Solution Versus Blood Cardioplegia in CABG
Status:
Completed
Trial end date:
2020-04-25
Target enrollment:
Participant gender:
Summary
Background: In cardiac surgery, myocardial protection is mandatory during cross clamp time
followed by reperfusion. Use of cardioplegic solutions preserves myocardial energy stores,
hindering electrolyte disturbances and acidosis during periods of myocardial ischemia. This
study was designed to compare the efficacy and safety of Histidine-tryptophan-ketoglutarate
(HTK) solution versus blood cardioplegia in coronary artery bypass graft surgery.
Methods: Three hundred and twenty patients were randomized into
Histidine-tryptophan-ketoglutarate (HTK) group and blood cardioplegia group. Ventilation
time, total bypass time, cross clamp time, length of ICU or hospital stay and the early
postoperative outcomes were analysed.